NEW YORK and BERLIN, Oct. 20, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the agenda for its virtual R&D Day. During this event, management and scientific leaders will provide a comprehensive review of atai’s diversified mental health pipeline.


Previous articlePsilera’s Award-Winning Co-Founders To Be Featured Speakers at Upcoming Industry Conferences Across the Country.
Next articlePT366 – Neurotransmitter Systems and Novel Psychedelic Molecules